Working...
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03028103
Brief Title: Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

First Submitted : December 19, 2016
First Submitted that Met QC Criteria : January 18, 2017
First Posted : January 23, 2017 (Estimate)

Last Update Submitted that Met QC Criteria : February 21, 2019
Last Update Posted : February 22, 2019